{"schema_version":"secwatch.filing_event.v1","accession":"0001022079-23-000091","form_type":"8-K","ticker":"DGX","cik":"0001022079","company_name":"QUEST DIAGNOSTICS INC","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.633949+00:00","generated_at":"2026-06-16T07:43:57.226263+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Quest Diagnostics Q1 revenue falls 10.7% to $2.33B; acquires Haystack Oncology for $300M","bullets":["Q1 net revenue $2.33B, down 10.7% YoY; base business revenue up 10% to $2.21B.","Reported diluted EPS $1.78 (down 39%); adjusted diluted EPS $2.04 (down 36.6%).","Full-year 2023 guidance: revenue $8.93B-$9.08B, adjusted EPS $8.45-$8.95.","Acquires Haystack Oncology for $300M cash at close plus up to $150M milestones; MRD liquid biopsy tech.","Deal expected to close Q2 2023; modest dilution for 3 years, accretive by 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001022079-23-000091","json":"https://secwatch.observer/filing/0001022079-23-000091.json","markdown":"https://secwatch.observer/filing/0001022079-23-000091.md","text":"https://secwatch.observer/filing/0001022079-23-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000091/0001022079-23-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000091/dgx-20230427.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T07:43:57.226263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5ea1d6f20286aecb36cd2007f6a21f45110b557c","claim":"QUEST DIAGNOSTICS INC updated its the quarter ended March 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On April 27, 2023, Quest Diagnostics Incorporated (the \"Company\") issued a press release announcing, among other things, its results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000091/0001022079-23-000091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f6df219cb734381301c08342a9ad219cb4556c17","claim":"QUEST DIAGNOSTICS INC reported Full Year 2023 results: revenue $8.93 billion $9.08 billion, EPS $7.52 $8.02. Guidance lowered.","evidence_excerpt":"Full year 2023 revenues now expected to be between $8.93 billion and $9.08 billion; reported diluted EPS now expected to be between $7.52 and $8.02","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1022079/000102207923000091/0001022079-23-000091-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$8.93 billion $9.08 billion"},{"label":"EPS","value":"$7.52 $8.02"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}